1.
J Med Chem
; 57(21): 9124-9, 2014 Nov 13.
Artículo
en Inglés
| MEDLINE
| ID: mdl-25368984
RESUMEN
Utilizing structure-based drug design, a novel dihydropyridopyrimidinone series which exhibited potent Hsp90 inhibition, good pharmacokinetics upon oral administration, and an excellent pharmacokinetic/pharmacodynamic relationship in vivo was developed from a commercial hit. The exploration of this series led to the selection of NVP-HSP990 as a development candidate.